Current Status: Completed Phase I Clinical Trial
|Name of Study||Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy (DC-TC)
|ClinicalTrials.gov Identifier||NCT01828762 - view study online here|
|Study Design||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
The safety and efficacy profiles of TC-DC are outstanding based on Phase II clinical trial of TC-DC therapy for metastatic melanoma IN USA. The most recent phase II clinical trial of metastatic melanoma has shown five-year survival rate is 54% in treatment group, and this therapy can significantly reduce the rate of tumor recurrence and metastasis, improve patient quality of life and extended lifetime.
Our China clinical trial is the result of collaboration between CBMG, California Stem Cell (CSC) and Shanghai‘s PLA 85 Hospital. It is the first immune cell clinical trial of its kind in China.
Multinational Contract Research Organization (CRO) CMIC-GCP has been contracted to manage the trial design and minimize delays.